Mohamed Mamdouh F A, Shaykoon Montaser Sh A, Abdelrahman Mostafa H, Elsadek Bakheet E M, Aboraia Ahmed S, Abuo-Rahma Gamal El-Din A A
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, 82524 Sohag, Egypt.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, 71524 Assiut, Egypt.
Bioorg Chem. 2017 Jun;72:32-41. doi: 10.1016/j.bioorg.2017.03.005. Epub 2017 Mar 19.
A group of novel chalcone derivatives comprising hydroxamic acid or 2-aminobenzamide group as zinc binding groups (ZBG) were synthesized. The structure of the prepared compounds was fully characterized by IR, NMR and elemental microanalyses. Most of the tested compounds displayed strong to moderate HDAC inhibitory activity. Some of these compounds showed potent anti-proliferative activity against human HepG2, MCF-7 and HCT-116 cell lines. In particular, compounds 4a and 4b exhibited significant anti-proliferative activity against the three cell lines compared to SAHA as reference drug and displayed promising profile as anti-tumor candidates. The results indicated that these chalcone derivatives could serve as a promising lead compounds for further optimization as antitumor agents.
合成了一组新型查尔酮衍生物,其包含异羟肟酸或2-氨基苯甲酰胺基团作为锌结合基团(ZBG)。通过红外光谱(IR)、核磁共振(NMR)和元素微量分析对所制备化合物的结构进行了全面表征。大多数测试化合物表现出强至中等的组蛋白去乙酰化酶(HDAC)抑制活性。其中一些化合物对人肝癌细胞系HepG2、人乳腺癌细胞系MCF-7和人结肠癌细胞系HCT-116显示出较强的抗增殖活性。特别是,与作为参考药物的伏立诺他相比,化合物4a和4b对这三种细胞系表现出显著的抗增殖活性,并显示出作为抗肿瘤候选物的良好前景。结果表明,这些查尔酮衍生物有望作为进一步优化的抗肿瘤药物先导化合物。